[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361115-105":59,"doc-detail-361115-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-novel-aerogel-delivery-system-reduces-drug-resistance-for-non-small-cell-lung-cancer-combination-therapy","A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy","","Lung cancer remains the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) as the predominant subtype. Although targeted therapies have progressed, prognosis is poor due to drug resistance. Combination therapy using docetaxel and gefitinib can be synergistic but is constrained by systemic side effects arising from nonspecific uptake. An inhalable aerogel-based nanocarrier was developed for efficient codelivery to boost lung tumor accumulation and reduce systemic toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-novel-aerogel-delivery-system-reduces-drug-resistance-for-non-small-cell-lung-cancer-combination-therapy/361115/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-novel-aerogel-delivery-system-reduces-drug-resistance-for-non-small-cell-lung-cancer-combination-therapy/361115.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is drug resistance a major issue in NSCLC treatment?","Question",{"text":112,"@type":113},"Drug resistance develops during tumor progression and persists despite therapeutic advances, limiting the effectiveness of multiple treatment modalities.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the main goal of the inhalable aerogel-based nanocarrier?",{"text":117,"@type":113},"To achieve efficient codelivery of docetaxel and gefitinib in the lung, enhancing tumor accumulation while reducing systemic toxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the aerogel nanocarrier improve therapeutic outcomes compared with monotherapy?",{"text":121,"@type":113},"Inhalation led to significant drug enrichment in tumors and produced tumor inhibition in an NSCLC xenograft model with reduced resistance versus monotherapy, supported by mechanistic effects on angiogenesis and apoptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361115,1790557360,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Medicine  \n|  RESEARCH ARTICLE  OPEN ACCESS \u003Cbr>A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy\u003Cbr>Dingwei Diao  | Yu Tong  | Jianxue Zhai  | Shijie Mai  | Xiguang Liu  | Xuguang Rao  | Kaican Cai  The Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China\u003Cbr>Correspondence: Xuguang Rao ([raoxuguang1971@i.smu.edu.cn](raoxuguang1971@i.smu.edu.cn)) | Kaican Cai ([doc_ckc@163.com](doc_ckc@163.com))\u003Cbr>Received: 24 December 2025 | Revised: 1 July 2026 | Accepted: 17 July 2026\u003Cbr>Keywords: combination therapy | nano-carrier | nebulized aerogel | non-small cell lung cancer (NSCLC) |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Lung cancer remains the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) representing the predominant subtype. Despite advances with molecularly targeted therapies, the prognosis remains poor because of drug resistance. Combination therapy with docetaxel and gefitinib offers synergistic potential but is limited by systemic side effects from nonspecific uptake. Here, we developed an inhalable aerogel-based nanocarrier for the efficient codelivery of docetaxel and gefitinib, designed to enhance lung tumor accumulation while reducing systemic toxicity. Inhalation administration resulted in significant drug enrichment in tumors and achieved a tumor inhibition rate of 55.4% ± 3.6% in an NSCLC xenograft model, with reduced resistance compared with monotherapy. Mechanistically, the aerogel synergistically suppressed angiogenesis and promoted apoptosis. These findings underscore the potential of inhalable aerogels as a promising strategy for effective NSCLC therapy and clinical translation. |  |\n| 1 | Introduction | and its complex interactions with the tumor microenvironment continue to impede progress in overcoming resistance [10–12] . |\n| Lung cancer represents the foremost cause of cancer-related | Therefore, effectively surmounting drug resistance in NSCLC is |\n| mortality globally, with non-small cell lung cancer (NSCLC) constituting approximately 85% of all cases, encompassing sub- | essential for improving treatment outcomes. |\n| types such as adenocarcinoma, squamous cell carcinoma, and | In recent decades, targeted therapies such as the epidermal |\n| large cell carcinoma [1, 2] . The principal therapeutic strategies | growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) |\n| for lung cancer include surgical resection, radiofrequency ab- | gefitinib have been extensively studied and have achieved tre- |\n| lation, chemotherapy, targeted therapy, and immunotherapy | mendous success in clinical practice [8, 9] . Although gefitinib |\n| [2–5] . As the most common subtype of lung cancer, non-small | improves patient prognosis and prolongs progression-free sur- |\n| cell lung cancer (NSCLC) remains a major clinical challenge. | vival, the emergence of drug resistance during treatment re- |\n| Although significant therapeutic advances have been achieved, | mains a major challenge. Combination therapy with multiple |\n| the prognosis for patients remains poor [6], largely because of in- | pharmacological agents has been employed to achieve synergis- |\n| trinsic and acquired drug resistance that emerges during tumor | tic effects and delay resistance, demonstrating improved ther- |\n| progression [7]. Drug resistance poses a critical barrier to multi- | apeutic efficacy. However, this strategy does not eliminate the |\n| ple therapeutic modalities [8, 9]. While numerous molecular sig- | adverse effects associated with nonspecific uptake by healthy |\n| naling pathways and genetic mechanisms underlying resistance | cells [13, 14]. Thus, there is an urgent need for strategies that en- |\n| have been identified, the pronounced heterogeneity of NSCLC | able the precise delivery of therapeutic agents. Addressing both |\n| Dingwei Diao and Yu Tong have contributed equally to this work and s","cbCairMVfUvZGLeF","https://ap.wps.com/l/cbCairMVfUvZGLeF","pdf",2890954,14,"English","# Introduction\n# Abstract","[{\"question\":\"Why is drug resistance a major issue in NSCLC treatment?\",\"answer\":\"Drug resistance develops during tumor progression and persists despite therapeutic advances, limiting the effectiveness of multiple treatment modalities.\"},{\"question\":\"What is the main goal of the inhalable aerogel-based nanocarrier?\",\"answer\":\"To achieve efficient codelivery of docetaxel and gefitinib in the lung, enhancing tumor accumulation while reducing systemic toxicity.\"},{\"question\":\"How does the aerogel nanocarrier improve therapeutic outcomes compared with monotherapy?\",\"answer\":\"Inhalation led to significant drug enrichment in tumors and produced tumor inhibition in an NSCLC xenograft model with reduced resistance versus monotherapy, supported by mechanistic effects on angiogenesis and apoptosis.\"}]","A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy | PDF",1790143178,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8cab772879018bfa96294b7e48ea0e8.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d25caa2470409de837580d6ce6cedafe.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad1bdcfbf1095cba43ca2a847ed8d6a8.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b017fc94ae0e3c5281a2df65ce8aaee2.webp",980,1287]